Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib (LOU064) in Inadequately Controlled Chronic Spontaneous Urticaria
NCT03926611Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of remibrutinib in chronic spontaneous urticaria (CSU) (7 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4. Started Jun 2019; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03926611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926611.